The US Biologics Competition Act and Biosimilar Red Tape Elimination Act

Home/Policies & Legislation | Posted 27/01/2023 post-comment0 Post your comment

The US introduced the Biologics Competition Act of 2022 (HR 887) in September 2022. This was followed by the introduction of the Biosimilar Red Tape Elimination Act in November 2022. Both acts seek to make biosimilar products more accessible and increase their uptake in the US.


The Biologics Competition Act of 2022 is a bipartisan act introduced by Representatives Mariannette Miller-Meeks, MD, R-Iowa; Greg Murphy, MD, R-North Carolina; Nanette Barragán, D-California; and Ann Kuster, D-New Hampshire. Whereas the Biosimilar Red Tape Elimination Act was introduced by Senator Mike Lee R‑Utah. 

The Biologics Competition Act Biologics of 2022 sets out to direct the Secretary of Health and Human Services (HHS) on the evaluation of process by which interchangeable biological products are approved. Specifically, the secretary of HHS is directed to complete a study evaluating how substitution of interchangeable biological products may be impeded, within a year of the act passing. A report will then be submitted to Congress on the results of the study. In addition, the HHS is required to make updates to the Purple Book (searchable, online database that contains information about biological products) to align communication of substitutability of interchangeable products with communication about therapeutic equivalence ratings.

In the US, biosimilars approved and granted interchangeable status can be substituted at the pharmacy level without the approval of the prescriber (similar to generics) [1]. To acquire interchangeable status, the biosimilar must undergo additional switching studies and these are expensive and time consuming, which creates a barrier to interchangeable approval. The Biosimilar Red Tape Elimination Act removes the requirement for these switching studies. Eliminating this barrier increases access to lower cost biosimilars and has potential to save payers and consumers billions of dollars.

To date, only three biosimilars have been granted interchangeability status. The first was Semglee (insulin glargine biosimilar) [2] and the second, Cimerli (ranibizumab), the first interchangeable ophthalmology biosimilar [3]. 

It is hoped that together, these acts will improve access to biosimilars, which offer more affordable treatment options to US citizens.

Related articles
Different approaches to the interchangeability of biosimilars

US Senate clarifies status of interchangeable biosimilar exclusivity 

House bill passes FDA funding fees but conflicts with Senate bill

USA BIOSIM Act introduction

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. FDA releases new information on interchangeable biologicals[]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from: 
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves first interchangeable insulin glargine biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves first interchangeable ranibizumab biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA publishes BsUFA III research roadmap
Harmonize V13F28
Home/Policies & Legislation Posted 03/03/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010